Clinical Trial Update: Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Ultratrace Iobenguane I-131 for Neuroblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Ultratrace Iobenguane I-131 (iobenguane I-131)

Snippet

Sponsor: Molecular Insight Pharmaceuticals, Inc. | Conditions: Neuroblastoma | Phase 2 | Status: WITHDRAWN